Researchers at Indiana University School of Medicine have developed a blood test for anxiety by examining biomarkers, which can determine a patient’s risk, severity, and the most effective treatment options. The test, currently being developed for wider use by MindX Sciences, can help provide a comprehensive report for patients and physicians using a single blood sample, potentially aiding in early diagnosis and targeted treatment.
Scientists at the Indiana University School of Medicine have successfully created a blood test for anxiety. The test analyzes biomarkers that enable them to objectively assess an individual’s likelihood of experiencing anxiety, the intensity of their current anxiety symptoms, and which therapies would likely treat their anxiety the best.
Having been validated by researchers, the test is now being advanced for widespread use among physicians by MindX Sciences.
“Many people are suffering from anxiety, which can be very disabling and interfere with daily life,” said professor of psychiatry Alexander Niculescu, MD, Ph.D. “The current approach is to talk to people about how they feel to see if they could be on medications, but some medications can be addictive and create more problems. We wanted to see if our approach to identifying blood biomarkers could help us match people to existing medications that will work better and could be a non-addictive choice.”
Niculescu’s past research has led to the development of blood tests for pain, depression/bipolar disorder, and post-traumatic stress disorder. This latest work, published in Molecular Psychiatry, uses similar methods for anxiety. The study included three independent cohorts—discovery, validation, and testing. Participants would complete a blood test every 3-6 months or whenever a new psychiatric hospitalization occurred. By examining the RNA biomarkers in the blood, researchers could identify a patient’s current state of anxiety and matches them with medications and nutraceuticals, showing how effective different options could be for them based on their biology.
“In addition to medications, there are other methods to treat anxiety, such as cognitive behavioral therapy or lifestyle changes,” Niculescu said. “But having something objective like this where we can know what someone’s current state is as well as their future risk and what treatment options match their profile is very powerful in helping people.”
A person’s biomarkers can also change over time. Niculescu said the test can help evaluate a person’s risk of developing higher levels of anxiety in the future as well as how other factors might impact their anxiety, like hormonal changes.
“There are people who have anxiety and it is not properly diagnosed, then they have panic attacks but think they’re having a heart attack and up in the ER with all sorts of physical symptoms,” Niculescu said. “If we can know that earlier, then we can hopefully avoid this pain and suffering and treat them earlier with something that matches their profile.”
Niculescu said this new test could also be used in combination with the other blood tests his research has led to, providing a more comprehensive view of a patient’s mental health and risk of future mental health concerns. Researchers can also use the test to develop new treatments for anxiety that are more targeted to individual biomarkers.
“This is something that could be a panel test as part of a patient’s regular wellness visits to evaluate their mental health over time and prevent any future distress,” Niculescu said. “Prevention is better in the long run, so our goal is to be able to provide a comprehensive report for patients and their physicians using simply one tube of blood.”
Reference: “Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs” by K. Roseberry, H. Le-Niculescu, D. F. Levey, R. Bhagar, K. Soe, J. Rogers, S. Palkowitz, N. Pina, W. A. Anastasiadis, S. S. Gill, S. M. Kurian, A. Shekhar, and A. B. Niculescu, 7 March 2023, Molecular Psychiatry.
DOI: 10.1038/s41380-023-01998-0
As a long-term male victim, with it still true that “an ounce of prevention is worth a pound of cure,” it just might suffice to diagnose and treat persons complaining/diagnosed with anxiety (especially women and more so mothers) based on three nearly standard tests: serum uric acid, ionic calcium and bone density. In the absence of adequate dietary supplies, long-term chronic nearly subclinical non-IgE-mediated allergy reactions (Dr. Arthur F. Coca, by 1935) and resultant chronic inflammation can cause hyperuricemia, a calcium deficiency and osteopenia, which can go undetected using serum calcium testing alone.
This sounds very interesting, but as someone with a mess of health problems that don’t show up in my bloodwork, I’m somewhat concerned that the same thing would occur here. i.e. people who have severe anxiety, but it doesn’t show up in this new test, and then are denied treatment.